A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

Conditions: Androgenetic Alopecia Interventions: Drug: placebo-Q2W; Drug: HMI-115-120mg-Q4W; Drug: HMI-115-240mg-Q4W; Drug: HMI-115, 240mg-Q2W Sponsors: Hope Medicine (Nanjing) Co., Ltd Recruiting

https://clinicaltrials.gov/study/NCT06118866

Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials

More News: Alopecia | Research | Study